Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape
Snapshot: 2026-09-04

Zhejiang Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 50 active clinical trials for multiple myeloma hosted across 19 tertiary medical centers in Zhejiang (including The First Affiliated Hospital, Zhejiang University School of Medicine, The First Affiliated Hospital of Wenzhou Medical University, The Second Affiliated Hospital, Zhejiang University School of Medicine, etc.).

Active Trials
50
Hospitals
19
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (19)

The First Affiliated Hospital, Zhejiang University School of MedicineThe First Affiliated Hospital of Wenzhou Medical UniversityThe Second Affiliated Hospital, Zhejiang University School of MedicineZhejiang Taizhou Hospital宁波市第一医院Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of MedicineThe Affiliated People's Hospital of Ningbo UniversityThe Second Affiliated Hospital of Wenzhou Medical UniversityThe Second Affiliated Hospital, Zhejiang University School of MedicineThe First Affiliated Hospital of Ningbo UniversityHangzhou First People's HospitalJiaxing First HospitalLishui Central HospitalZhejiang Provincial People's Hospital浙江大学附属第一医院The First Affiliated Hospital, Zhejiang University School of MedicineDongyang People's HospitalYiwu Central HospitalThe First Affiliated Hospital of Zhejiang Chinese Medical University

Active Studies in Zhejiang (50)

Population synthesized by CMDN

Showing 0 published English records of 50 registry trials.

All 50 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.